CAR T-Cell therapy for Myeloma: Where are we now and what is needed to move CAR T-cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Since 2021, two B-Cell Maturation Antigen (BCMA) directed chimeric antigen receptor T-cell (CAR T-cell) therapies, Idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel), have been approved by the US FDA for relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody. The two products have both shown unprecedented activity in RRMM, but relapses …